The global Bulimia Nervosa Treatment Market experienced significant growth in 2021 and is projected to continue expanding at a rapid pace throughout the forecast period. This growth can be attributed to several factors, including the increasing prevalence of eating disorders among the elderly population and the heightened focus on research and development to develop innovative therapies. However, the limited availability of authentic and approved medications for the treatment of bulimia nervosa remains a major hindrance to the market's revenue growth.

Bulimia nervosa, also known as bulimia, is a severe eating disorder that can be life-threatening. Individuals suffering from bulimia engage in covert binge-eating episodes and subsequently engage in purging behaviors to rid themselves of the excess calories consumed. Symptoms of bulimia nervosa include an obsession with weight and body shape, fear of weight gain, self-induced vomiting, excessive exercise to prevent weight gain, frequent consumption of abnormally large amounts of food, and the use of laxatives, diuretics, or enemas after eating.

Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5505

There are various factors driving the revenue growth of the bulimia nervosa treatment market. One of the primary drivers is the increasing prevalence of bulimia nervosa. Lifetime prevalence of bulimia nervosa among adults is estimated to be 1.0%, with females having a five times higher prevalence than males. The impairments in the patients' lifestyle caused by bulimia nervosa are treated with medications available in the market, contributing to revenue growth. According to the Sheehan Disability Scale, 43.9% of individuals with bulimia nervosa experience severe impairment, while 78.0% experience some form of disability. Furthermore, symptomatic treatment using antidepressants helps prevent complications associated with bulimia nervosa. Between 2015 and 2018, 13.2% of adults used antidepressants, with higher usage among women and an increase with age. These factors play a crucial role in the revenue growth of the bulimia nervosa treatment market.

On the other hand, several factors impede the revenue growth of the bulimia nervosa market. The scarcity of specific treatments in emerging nations is a significant obstacle. Additionally, the availability of various therapies in the market, such as psychotherapy, hinders revenue growth as the disorder is not easily diagnosed by doctors and patients alike. Moreover, the high cost of bulimia nervosa treatment adversely affects the market. The side effects associated with antidepressant drugs used for symptomatic relief also contribute to the hindrance in revenue growth.

The rise in research and development activities focused on the advanced treatment of bulimia nervosa presents opportunities for revenue growth in the market. Increased government participation and initiatives to enhance healthcare services worldwide further contribute to market growth. As the symptoms of each patient vary, there is an opportunity for scientists and innovators to develop effective personalized medications for individuals with bulimia nervosa, thereby ensuring sustained revenue growth.

To know more about the latest insights of the report, visit @ https://www.reportsanddata.com/request-latest-insight/5505

Geographically, North America is expected to dominate the market share throughout the forecast period. The region benefits from the introduction of new treatment options, increased healthcare expenditures, and the availability of various treatment choices, leading to revenue growth. Furthermore, growing awareness of the disease among the population contributes to market expansion. Asia Pacific is projected to be the fastest-growing region, driven by the increasing geriatric population in countries like China and India, the presence of generic manufacturers, and the expansion of healthcare facilities.

In terms of key market trends and innovation, ongoing clinical trials are exploring the effectiveness of serotonergic antidepressants in treating bulimia nervosa, with results expected by March 2023. Additionally, a phase 2 clinical trial conducted between February 2020 and June 2022 investigated the effects of estradiol and progesterone on binge eating in women with bulimia, suggesting a hormone-sensitive aspect to the disorder. Future research in this area may guide advancements in neuroendocrine, neuronal, and brain activity and function related to bulimia nervosa.

The competitive landscape of the market showcases both organic and inorganic strategies. Fluoxetine (Prozac), a selective serotonin reuptake inhibitor, is the only antidepressant approved by the U.S. Food and Drug Administration (FDA) for treating bulimia nervosa. In 2019, two prominent eating disorder support groups, the National Eating Disorders Association (NEDA) and the National Association for Males with Eating Disorders (NAMED), merged to strengthen the eating disorders community and improve access to services and support. The major companies operating in the market include AstraZeneca plc, Sun Pharmaceutical Industries Ltd, GSK plc, Eli Lilly & Company, Bayer AG, Pfizer Inc., Sorrento Therapeutics, Inc., Johnson & Johnson, and Lupin Limited.

In conclusion, our report provides comprehensive historical data, forecasts, and revenue growth analysis at the global, regional, and country levels. It includes industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and revenue share contribution for each regional and country market. Additionally, the report offers industry analysis, competitive landscape, company financials, and impact analysis. The report also covers various aspects such as distribution channels, end-use, disease type, route of administration, treatment options, dosage forms, and regional outlook, providing a holistic view of the market.

Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5505

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs